GC Cell

지씨셀 · 144510

Industrials Commercial Services · KOSDAQ

Small-cap

Market cap US$204.3M (₩281.9B)

Overview

GC Cell develops living-cell medicines, therapies that use a patient's own or donor cells, modified outside the body, to treat or prevent disease.

Its products and services are used by hospitals, clinics, and research institutions, and it is listed on KOSDAQ, South Korea's technology and small-cap exchange. The business spans five distinct lines: cell therapy development, laboratory specimen-testing services, umbilical-cord-blood banking, bio-logistics, and contract development and manufacturing (CDMO) for other life-science companies.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$119.9M

▼ −5.1% YoY

Operating profit · FY2025

−US$10M

Loss narrowed

Net income · FY2025

−US$198.2M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$135.9M(₩187.5B)	US$126.4M(₩174.5B)	US$119.9M(₩165.5B)
Operating profit	US$3M(₩4.1B)	−US$14.5M(−₩20B)	−US$10M(−₩13.8B)
Net income	US$57.3K(₩79.1M)	−US$54.9M(−₩75.7B)	−US$198.2M(−₩273.5B)

Revenue

FY2023US$135.9M
FY2024US$126.4M
FY2025US$119.9M

Operating profit

FY2023US$3M
FY2024−US$14.5M
FY2025−US$10M

Net income

FY2023US$57.3K
FY2024−US$54.9M
FY2025−US$198.2M

Key ratios (FY2025)

ROE

-143.7%

Debt/Eq

59.5%

Op. margin

-8.3%

Net margin

-165.3%

Rev. YoY

▼ −5.1%

Why it matters

The filing states that GC Cell acquired its cell-therapy business from Nokchipja (Green Cross) and later expanded into NK- and T-cell therapy, reflecting a deliberate broadening of its therapeutic pipeline.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?